Answers are grounded in this paper and cite their sources.
Clinical review reports advancing pharmacotherapies and lifestyle interventions in metabolic dysfunction-associated steatotic liver disease, highlighting an evolving treatment landscape.
Metabolic dysfunction-associated steatotic liver disease (MASLD) has emerged as a challenging multi-system global health problem, affecting approximately one-third of the world's population. Lifestyle modifications remain the cornerstone of MASLD management, which poses challenges in this population. The recent US Food and Drug Administration approval of resmetirom and semaglutide for the treatment of metabolic dysfunction-associated steatohepatitis with fibrosis signifies a substantial transformation in the therapeutic landscape. Other new therapeutic options are emerging, with encouraging phase 3 data from several agents spanning diverse mechanisms of action. This review summarizes the contemporary non-pharmacological and pharmacological approaches to MASLD.
No takes yet. Share an insight, caveat, or question.
Shenoy et al. (2026) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: